NEW YORK (GenomeWeb) — Bio-Rad reported after the close of the market Tuesday an 11 percent decrease in third quarter revenues, including a 13 percent decrease in sales for its Life Science segment.

For the three months ended Sept. 30, Bio-Rad reported revenues of $470 million compared to $530.6 million in the year-ago period, and below analysts’ consensus estimate of $495.6 million. On a currency-neutral basis, Bio-Rad's Q3 revenues decreased 2.2 percent year over year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Oct
02
Sponsored by
Roche

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.